Am I eligible for this study? If you are over the age of 18 and have recurrent or persistent cancer, and your cancer expresses a protein called HER2, you may be able to participate. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Be sure to take […]
Read MoreAbout This Study EAY191-N5 is part of the ComboMATCH precision medicine initiative for people that have recurrent or persistent HER2+ gynecologic cancers and other solid tumors. The ComboMATCH registration trial studies show how well treatment that is directed by genetic testing works in treating patients with solid tumors that have spread to nearby tissue or […]
Read MoreClinical Studies FAQ
Read MoreThe EAY191-N5 Study FAQ
Read More